Rhodotorula glutinis fungemia in a liver-kidney transplant patient

Transplant Infectious Disease

Volumn 10, Issue 3, 2008, Pages 197-200

  Riedel, D J ^a,b   Johnson, J K ^b   Forrest, G N ^b  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Candida glabrata; Fungemia; Liver kidney transplant; Rhodotorula; Rhodotorula glutinis

Indexed keywords

CEFEPIME; CIPROFLOXACIN; COTRIMOXAZOLE; FLUCONAZOLE; HEPATITIS B ANTIBODY; LAMIVUDINE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; TACROLIMUS; VORICONAZOLE;

ADULT; ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; CASE REPORT; FATALITY; FUNGEMIA; GRAFT RECIPIENT; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RHODOTORULA GLUTINIS;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; FUNGEMIA; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RHODOTORULA;

EID: 43949126884     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2007.00265.x     Document Type: Article

References (18)

1. Lunardi LW, Aquino VR, Zimerman RA, Goldani LZ. Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital. Clin Infect Dis 2006 43 : e60 e63.
2. Vartivarian SE, Anaissie EJ, Bodey GP. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin Infect Dis 1993 17 (Suppl 2) : S487 S491.
3. Pfaller MA, Diekema DJ, Rinaldi MG, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005 43 : 5848 5859.
4. Zaas AK, Boyce M, Schell W, Lodge BA, Miller JL, Perfect JR. Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates. J Clin Microbiol 2003 41 : 5233 5235.
5. Diekema DJ, Petroelje B, Messer SA, Hollis RJ, Pfaller MA. Activities of available and investigational antifungal agents against Rhodotorula species. J Clin Microbiol 2005 43 : 476 478.
6. Navarro JT, Lauzurica R, Gimenez M. Rhodotorula rubra infection in a kidney transplant patient with pancytopenia. Haematologica 2001 86 : 111.
7. Spellberg BJ, Filler SG, Edwards JE Jr. Current treatment strategies for disseminated candidiasis. Clin Infect Dis 2006 42 : 244 251.
8. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006 20 : 485 506.
9. Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. Susceptibility profile of 29 clinical isolates of Rhodotorula spp. and literature review. J Antimicrob Chemother 2005 55 : 312 316.
10. Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000 182 : 1791 1795.
11. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997 41 : 2326 2332.
12. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998 36 : 2950 2956.
13. Maligie MA, Selitrennikoff CP. Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother 2005 49 : 2851 2856.
14. Forrest GN, Rasetto F, Akpek G, Philosophe B. Safety and efficacy of micafungin in transplantation recipients. Transplantation 2006 82 : 1549.
15. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 2003 41 : 1440 1446.
16. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004 42 : 3142 3146.
17. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006 44 : 529 535.
18. Panackal AA, Gribskov JL, Staab JF, Kirby KA, Rinaldi M, Marr KA. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006 44 : 1740 1743.